Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3275

Metformin Inhibits Growth of Hepatocellular Carcinoma Cells by Inducing Apoptosis Via Mitochondrion-mediated Pathway  

Xiong, Yu (Department of Hepatobiliary Surgery, Zhongshan Hospital, Xiamen University)
Lu, Qing-Jun (Department of General Surgery, Binzhou Central Hospital)
Zhao, Jing (Department of Cardiac Surgical Intensive Care Unit, Provincial Hospital Affiliated to Shandong University)
Wu, Guo-Yang (Department of Hepatobiliary Surgery, Zhongshan Hospital, Xiamen University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3275-3279 More about this Journal
Abstract
Recently, population-based studies of type 2 diabetes patients have provided evidence that metformin treatment is associated with a reduced cancer incidence and mortality, but its mode of action remains unclear. Here we report effects of metformin on hepatocellular carcinoma (HCC) Hep-G2 cells and details of molecular mechanisms of metformin activity. Our research indicates that metformin displays anticancer activity against HCC through inhibition of the mTOR translational pathway in an AMPK-independent manner, leading to G1 arrest in the cell-cycle and subsequent cell apoptosis through the mitochondrion-dependent pathway. Furthermore, we showed that metformin strongly attenuated colony formation and dramatically inhibited Hep-G2 tumor growth in vivo. In conclusion, our studies suggested that metformin might have potential as a cytotoxic drug in the prevention and treatment of HCC.
Keywords
Metformin; HCC; mTOR; apoptosis; signaling pathway;
Citations & Related Records
연도 인용수 순위
  • Reference
1 An D , Kewalramani G, Chan JK Y et al (2006). Diabetologia, 49, 2174-84.   DOI
2 Avila MA, Berasain C, Sangro B, et al (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84.   DOI
3 Bailey CJ, Turner RC (1996). Metformin. N Engl J Med, 334, 574-9.   DOI   ScienceOn
4 Bolster DR, Crozier SJ, Kimball SR, et al (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem, 277, 977-80.
5 Bowker SL, Majumdar SR, Veugelers P et al (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8.   DOI   ScienceOn
6 Buzzai M, Jones RG, Amaravadi RK (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52.   DOI
7 Cantrell LA, Zhou C, Mendivil A, et al (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic Oncology, 116, 92-8.   DOI
8 Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapie on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77.   DOI
9 Daniels D, Grytdal S, Wasley A (2009). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ, 58, 1-27.
10 Dowling RJO, Zakikhani M, Fantus IG, et al (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12.   DOI   ScienceOn
11 Duncan B, Schmidt MI (2009). Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research. Diabetes Care, 32, 1748-50.   DOI
12 Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5.   DOI
13 Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20.   DOI
14 Gotlieb WH, Saumet J, Beauchamp MC (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 110, 246-50.   DOI
15 Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.   DOI
16 Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11.   DOI
17 Kalender A, Selvaraj A, Kim SY, et al (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab, 11, 390-401.   DOI
18 Holland EC, Sonenberg N, Pandolfi PP, et al (2004). Signaling control of mRNA translation in cancer pathogenesis. Oncogene, 23, 3138-44.   DOI
19 Huang X, Wullschleger S, Shpiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21.   DOI
20 Kahn BB, Alquier T, Carling D, et al (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1, 15-25.   DOI   ScienceOn
21 Lee MS, Hsu CC, Wahlqvist M, et al (2011). Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 20.   DOI
22 Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.   DOI
23 Li DH, Ching JS, Yeung M, et al (2009). Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-8.   DOI
24 Sahra IB, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86.   DOI   ScienceOn
25 Wright JL, Stanford JL (2009). Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control, 20, 1617-22.   DOI
26 Schneider MB, Matsuzaki H, Haorah J, et al (2001). Prenvention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 120, 1263-70.   DOI
27 Soranna D, Scotti L, Zambon A (2012). Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. The Oncologist, 17, 1083-7159.
28 Wang LW, Li ZS, Zou DW, et al (2008). Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol, 14, 7192-8.   DOI
29 Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84.   DOI   ScienceOn
30 Yu Y, Sato JD (1999). MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol, 178, 235-46.   DOI   ScienceOn
31 Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Res, 66, 10269-73.   DOI
32 Zhu Z, Jiang W, Thompson MD, et al (2011). Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog, 10, 17.   DOI